OA10133A - Inhibition of retrovirus infection - Google Patents

Inhibition of retrovirus infection Download PDF

Info

Publication number
OA10133A
OA10133A OA60622A OA60622A OA10133A OA 10133 A OA10133 A OA 10133A OA 60622 A OA60622 A OA 60622A OA 60622 A OA60622 A OA 60622A OA 10133 A OA10133 A OA 10133A
Authority
OA
OAPI
Prior art keywords
cys
pro
lys
gly
slpi
Prior art date
Application number
OA60622A
Other languages
English (en)
Inventor
Stephen Eisenberg
Sharon M Wahl
Robert C Thompson
Original Assignee
Amgen Boulder Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc, Us Health filed Critical Amgen Boulder Inc
Publication of OA10133A publication Critical patent/OA10133A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
OA60622A 1992-09-09 1995-03-09 Inhibition of retrovirus infection OA10133A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94336992A 1992-09-09 1992-09-09

Publications (1)

Publication Number Publication Date
OA10133A true OA10133A (en) 1996-12-18

Family

ID=25479533

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60622A OA10133A (en) 1992-09-09 1995-03-09 Inhibition of retrovirus infection

Country Status (23)

Country Link
EP (1) EP0666755B1 (fr)
JP (2) JP3517238B2 (fr)
KR (1) KR100273620B1 (fr)
AT (1) ATE238062T1 (fr)
AU (1) AU681350B2 (fr)
CA (1) CA2141951C (fr)
CZ (1) CZ286953B6 (fr)
DE (1) DE69332904T2 (fr)
DK (1) DK0666755T3 (fr)
ES (1) ES2197153T3 (fr)
FI (1) FI951078A0 (fr)
HU (1) HU218892B (fr)
NO (1) NO315546B1 (fr)
NZ (1) NZ256246A (fr)
OA (1) OA10133A (fr)
PL (1) PL307864A1 (fr)
PT (1) PT666755E (fr)
RO (1) RO116164B1 (fr)
RU (1) RU2126266C1 (fr)
SG (1) SG48115A1 (fr)
SK (1) SK281127B6 (fr)
UA (1) UA41338C2 (fr)
WO (1) WO1994006454A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144488A (zh) * 1994-03-23 1997-03-05 东京田边制药株式会社 新型呼吸道病毒性疾病治疗药物
AU6530696A (en) * 1995-07-24 1997-02-18 Tokyo Tanabe Company Limited Remedy for viral diseases
DK0861085T3 (da) 1995-11-13 2005-11-21 Vitaleech Bioscience N V Antivirale isolater opnået fra igler
AU780121B2 (en) * 1999-05-13 2005-03-03 Japan Science And Technology Agency Inhibitors for viral infection targeting integrase N-terminal region
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
WO2005046732A2 (fr) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methodes et compositions d'inhibition de la replication du vih-1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340877C (fr) * 1987-12-28 2000-01-18 Takashi Sugiyama Polypeptide inhibant l'elastage et procede de production par la technologie de l'adn recombinant
JP2804979B2 (ja) * 1988-11-28 1998-09-30 日本ケミカルリサーチ株式会社 エイズ治療および阻害剤
CA2007083A1 (fr) * 1989-01-09 1990-07-09 Nobuhiko Katunuma Usage pharmaceutique du trypstatin
DE69029970T2 (de) * 1989-08-16 1997-06-19 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
DK0506769T3 (da) * 1989-12-18 1994-11-28 Transgene Sa Farmaceutisk præparat til behandling eller forebyggelse af retrovirus-infektioner
GR1001044B (el) * 1991-06-03 1993-04-28 Logothetou Rella Eleni Μηχανισμός διή?ησης νεοπλασματικών κυττάρων και η χρήση του αναστολέα της Ca2+ -εξαρτώμενης ουδέτερης πρωτεάσης για την παρασκευή φαρμακευτικών αντικαρκινικών συν?έσεων.

Also Published As

Publication number Publication date
AU681350B2 (en) 1997-08-28
HU9500682D0 (en) 1995-04-28
AU4853093A (en) 1994-04-12
ES2197153T3 (es) 2004-01-01
HU218892B (hu) 2000-12-28
DE69332904D1 (de) 2003-05-28
CA2141951A1 (fr) 1994-03-31
PL307864A1 (en) 1995-06-26
CZ286953B6 (en) 2000-08-16
CZ55995A3 (en) 1996-01-17
FI951078A (fi) 1995-03-08
WO1994006454A2 (fr) 1994-03-31
NO315546B1 (no) 2003-09-22
JP3517238B2 (ja) 2004-04-12
RU95109909A (ru) 1997-03-27
EP0666755B1 (fr) 2003-04-23
DE69332904T2 (de) 2003-11-06
UA41338C2 (uk) 2001-09-17
NO950897D0 (no) 1995-03-08
JPH08505042A (ja) 1996-06-04
CA2141951C (fr) 2007-04-24
SK29795A3 (en) 1997-02-05
HUT75126A (en) 1997-04-28
NO950897L (no) 1995-03-08
SG48115A1 (en) 1998-04-17
PT666755E (pt) 2003-09-30
RO116164B1 (ro) 2000-11-30
FI951078A0 (fi) 1995-03-08
SK281127B6 (sk) 2000-12-11
KR950703357A (ko) 1995-09-20
RU2126266C1 (ru) 1999-02-20
EP0666755A1 (fr) 1995-08-16
WO1994006454A3 (fr) 1994-08-18
KR100273620B1 (ko) 2000-12-15
DK0666755T3 (da) 2003-08-04
NZ256246A (en) 1997-08-22
JP2004002455A (ja) 2004-01-08
ATE238062T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
JP2656938B2 (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
JPH11507632A (ja) 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
KR19990082084A (ko) 인터페론으로 선행치료한 hcv 환자를 재치료하기 위한 제약학적 조성물
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
AU1821295A (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US6017880A (en) Inhibition of retrovirus infection
OA10133A (en) Inhibition of retrovirus infection
JPH07267874A (ja) Ｈｉｖ感染に対する組合せ化学療法
US6869925B1 (en) Inhibition of retrovirus infection
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
KR20050057329A (ko) ＨＩＶ ｇｐ41-유래된 펩티드의 향상된 투여를 위한제약학적 조성물 및 이의 치료적 용도
EP0960886A1 (fr) Peptide T et peptides associes destines au traitement des inflammations, notamment la sclerose en plaques
JPH10251159A (ja) Ｉｌ−６を含む血清尿酸値低下剤
EP1497323B1 (fr) Constructions peptidiques a ramifications multiples comprenant entre 2 et 16 ramifications du peptide rqgys ou entre 8 et 16 ramifications du peptide rqgy provenant de la glycoproteine gp41 du vih
JPWO2008050830A1 (ja) 抗ｈｉｖ剤
AU763289C (en) Use of GM-CSF to inhibit development of drug resistance in HIV+ patients
WO2000045833A1 (fr) Systeme de resistance aux medicaments du vih
Pomerantz et al. Therapy of human immunodeficiency virus infections
WO1995023610A1 (fr) Compositions pharmaceutiques contenant du thymoctonan et de l'azt
HU203971B (en) Process for producing synergetic combination pharmaceutical compositions comprising 3'-azido-3'-deoxythymidine and one more active ingredient